Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Tekmira Pharmaceuticals Corporation    TKM   CA87911B2093

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Tekmira Pharmaceuticals Corporation : Tekmira to License Technology to Monsanto for Weed Control Research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2014 | 03:00pm CEST
By Everdeen Mason 

Tekmira Pharmaceuticals Corp. agreed to allow agriculture business Monsanto Co. to license use of its proprietary delivery technology, a deal Tekmira says is worth up to $86.2 million.

Tekmira shares shot up 33% in premarket trading following the deal's announcement.

Tekmira, which focuses on RNA interference therapeutics, will provide lipid formulations to Monsanto, which will be used for the latter company's research on new pest, virus and weed control options for agriculture.

The option agreement between the two companies will last four years, and Monsanto will pay Tekmira an option exercise fee for the exclusive right use Tekmira's technology in agriculture. Tekmira said it expects a near term payment of $16.5 million.

Monsanto, which is the largest seed company by sales, has benefited from a long-running farm boom in the U.S. and South America driven by high prices for corn and other commodities.

Write to Everdeen Mason at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEKMIRA PHARMACEUTICALS CO
06/02 Arbutus to Participate in Upcoming Investor Conferences
05/22 Arbutus Presents HBV Drug Combination Studies at ICAR
05/04 Arbutus Announces Corporate Update and First Quarter 2017 Financial Results
05/04 ARBUTUS BIOPHARMA CORP : Investor Network: Arbutus Biopharma Corporation to Host..
05/02 Arbutus Announces Conference Call to Provide a Corporate Update and First Qua..
04/22 Arbutus Announces ARB-1467 Data Presentation at EASL
04/13 Arbutus Injunction Survives Attempted Appeal by Acuitas
03/23 Arbutus Announces Appointment of Daniel Burgess to Board of Directors
03/21 Arbutus Announces Year-End 2016 Financial Results
03/16 Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messeng..
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 WHO approves rapid test for Ebola
2015 BIOTECH STOCKS : What's Hot, What's Not - As Seen By Market-Makers, Their Client..
2015 U.S. to pull troops from Ebola zone
2015 SEEKING ALPHA'S BIOTECH WEEKLY : Questioning Gilead, MannKind To Market, And Mor..
2015 TEKMIRA : Bad Idea Genes
Advertisement
Financials ($)
Sales 2017 1,73 M
EBIT 2017 -77,1 M
Net income 2017 -72,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 111x
Capi. / Sales 2018 29,1x
Capitalization 193 M
More Financials
Chart TEKMIRA PHARMACEUTICALS CO
Duration : Period :
Tekmira Pharmaceuticals Co Technical Analysis Chart | TKM | CA87911B2093 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 7,53 $
Spread / Average Target 115%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Murray President, Chief Executive Officer & Director
Vivek Ramaswamy Chairman
Bruce G. Cousins Chief Financial Officer & Executive Vice President
Peter Lutwyche Chief Technology Officer
Michael J. Sofia Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEKMIRA PHARMACEUTICAL..0.00%193
INCYTE CORPORATION29.96%26 684
QUINTILES IMS HOLDINGS..17.65%19 309
LONZA GROUP27.49%16 098
CELLTRION, INC.--.--%12 362
ALKERMES PLC4.89%8 750
More Results